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Introduction: The current mainstay of the treatment of thrombotic antiphospholipid syndrome
(APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin.
Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to
be effective and safe compared with warfarin for the treatment of venous thromboembolism
(VTE) in major phase III prospective, randomized controlled trials (RCTs), but the results
may not be directly generalizable to patients with APS. Aims: The primary aim is to demon-
strate, in patients with APS and previous VTE, with or without systemic lupus erythematosus
(SLE), that the intensity of anticoagulation achieved with rivaroxaban is not inferior to that of
warfarin. Secondary aims are to compare rates of recurrent thrombosis, bleeding and the
quality of life in patients on rivaroxaban with those on warfarin. Methods: Rivaroxaban in
antiphospholipid syndrome (RAPS) is a phase II/III prospective non-inferiority RCT in which
eligible patients with APS, with or without SLE, who are on warfarin, target international
normalized ratio (INR) 2.5 for previous VTE, will be randomized either to continue warfarin
(standard of care) or to switch to rivaroxaban. Intensity of anticoagulation will be assessed
using thrombin generation (TG) testing, with the primary outcome the percentage change in
endogenous thrombin potential (ETP) from randomization to day 42. Other TG parameters,
markers of in vivo coagulation activation, prothrombin fragment 1.2, thrombin antithrombin
complex and D-dimer, will also be assessed. Discussion: If RAPS demonstrates i) that the
anticoagulant effect of rivaroxaban is not inferior to that of warfarin and ii) the absence of any
adverse effects that cause concern with regard to the use of rivaroxaban, this would provide
sufficient supporting evidence to make rivaroxaban a standard of care for the treatment of
APS patients with previous VTE, requiring a target INR of 2.5. Lupus (2015) 24, 1087–1094.
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Introduction
Thrombotic antiphospholipid syndrome (APS) is
an acquired autoimmune disorder characterized
by venous and/or arterial thromboembolism asso-
ciated with persistent antiphospholipid antibodies
(aPL).1–3 The current mainstay of the treatment
of thrombotic APS is long-term anticoagulation
Correspondence to: Hannah Cohen, Department of Haematology,
University College London (UCL) Hospitals NHS Foundation
Trust, 250 Euston Road, London, NW1 2PG, UK.
Email: hannah.cohen@uclh.nhs.uk
Received 6 November 2014; accepted 17 March 2015
! The Author(s), 2015. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav 10.1177/0961203315581207
with oral vitamin K antagonists (VKAs) such as
warfarin. APS may occur alone, or with another
autoimmune disease. Approximately 30%–40% of
patients with systemic lupus erythematosus (SLE)
have aPL4 and 30%–40% of this group will develop
thrombotic APS,5,6 which is considered to be a
major adverse prognostic factor in patients with
SLE.5 Appropriate management of thrombotic
APS is of key importance to minimize its deleteri-
ous clinical impact.
Prospective, randomized controlled trials
(RCTs) support the current recommendation of
anticoagulation at a target international normal-
ized ratio (INR) of 2.5 (range 2.0–3.0) for patients
with APS, with or without SLE, presenting with a
ﬁrst venous thromboembolism (VTE) event, or a
recurrent VTE event which occurred whilst oﬀ
anticoagulation.7–10 However, warfarin, the most
widely used VKA in the United Kingdom (UK),
has a slow onset of action (three to ﬁve days), a
narrow therapeutic window, numerous drug and
dietary interactions, and potential for variation of
action with alcohol, intercurrent illness, exercise
and smoking, and regular INR monitoring is
required. VKAs present particular problems
in patients with APS. First, VKA monitoring in
patients with aPL can be complicated by the variable
responsiveness of thromboplastin reagents to lupus
anticoagulant (LA), which may in turn potentially
inﬂuence the validity of the INR in patients with
APS. Secondly, LA detection in patients onwarfarin
may be problematic because of the prolonged basal
clotting time.11 This potentially limits the ability to
diagnose APS in patients on VKAs and also to
monitor aPL status in those with an established
diagnosis. The limitations of warfarin and other
conventional anticoagulants have driven a search
for new alternative anticoagulants.
The new generation non-VKA oral anticoagu-
lants (NOACs) represent a major advance as,
unlike warfarin, they are ﬁxed dose with predictable
eﬀect and therefore do not require regular anti-
coagulant monitoring. In addition, they are not
aﬀected by changes in diet and alcohol intake and
have fewer drug interactions that aﬀect anticoagu-
lant intensity, which would be expected to result in
improved quality of life (QoL) for patients. Major
phase III RCTs have established that rivaroxaban
(Xarelto; Bayer HealthCare) and dabigatran
(Pradaxa; Boehringer Ingelheim Ltd), and more
recently apixaban (Eliquis; Bristol-Myers
Squibb-Pﬁzer) and edoxaban (Lixiana), have
comparable eﬃcacy and safety to warfarin in the
treatment of patients with VTE.12–18 In 2011, rivar-
oxaban was licenced by the European Medicines
Agency (EMA) for the treatment of deep vein
thrombosis (DVT), prevention of recurrent DVT
and pulmonary embolism (PE) following an acute
DVT in adults. In December 2012, rivaroxaban was
also licensed by the EMA for the treatment of acute
symptomatic PE with or without symptomatic
DVT.19 More recently, dabigatran and apixaban
have been licensed by the EMA for the treatment
of patients with VTE.20,21 Rivaroxaban and dabiga-
tran are endorsed for use in patients with VTE by the
National Institute for Health and Care Excellence
(NICE) in England.22–25 All three agents are
approved for use in the treatment of VTE by the
United States Food and Drug Administration
(FDA).26–28 Among patients with acute VTE,
approximately 10% have APS,29 and it is therefore
likely that some patients with APS were included in
the phase III RCTs of NOACs versus VKAs in
patients with VTE. However, aPL status was not
systematically documented in these trials,12–18 and
their results may therefore not be directly generaliz-
able to patients with APS where there remains an
unmet need.
Thrombin is a pivotal component of the haemo-
static mechanism, with increased ex vivo thrombin
generation (TG) a key marker of thrombogenic
potential with predictive value for the development
of recurrent VTE.30,31 Generation of thrombin via
the tissue factor (TF) pathway is integral to the
blood coagulation process, and thus, assessment
of TF-triggered TG provides a useful means of
studying the inhibitory actions of antithrombotic
agents.32 TG testing provides information about
the dynamics of ex vivo thrombin generation,
with the TG curve described in terms of: the lag-
time, the time to peak, peak thrombin concentra-
tion, and endogenous thrombin potential (ETP),
the area under the TG curve. Markers of in vivo
coagulation activation, prothrombin fragment 1.2
(F1.2), thrombin-antithrombin complex (TAT)
and D-dimer (a marker of activation of ﬁbrinolysis
secondary to coagulation activation), also provide
information about an individual’s thrombogenic
potential,30,31,33–38 and anticoagulation reduces the
levels of these markers.39–41 Warfarin (in non-APS
patients) at a target INR of 2.5 (range 2.0–3.0) has
been shown to reduce the ETP by 30%–50% com-
pared with the pre-warfarin result42 or normal con-
trols.43 It has been indicated in in vitro studies that
rivaroxaban can downregulate and completely sup-
press the process of thrombin generation in whole
blood and platelet-rich plasma using TG testing,44
and that the ETP is an appropriate measure of the
intensity of the anticoagulant eﬀect in individuals on
rivaroxaban.45,46 Rivaroxaban was selected for
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RAPS as its use was better established for VTE
treatment at the time of setting up the trial.
The primary aim is to demonstrate, in patients
with thrombotic APS with or without SLE, that the
intensity of anticoagulation achieved with rivarox-
aban is not inferior to that of warfarin. Secondary
aims are to compare rates of recurrent thrombosis
and bleeding, and the QoL in patients on rivarox-
aban with those on warfarin.
Methods
Study design
RAPS is a phase II/III prospective, randomized
controlled non-inferiority open-label clinical trial
in patients with thrombotic APS, with or without
SLE, currently receiving warfarin therapy. Eligible
patients, who have provided their fully informed
signed consent, will be randomized 1:1 to warfarin
(continuation with standard of care) or rivaroxa-
ban 20mg daily. The RAPS clinical trial schema
is shown in Figure 1 (Appendix A). The
Appendix (A-I) is available on the Lupus website
(http://lup.sagepub.com), with all references
included in the manuscript. Potential participants
will be identiﬁed by their physician during routine
outpatient visits to the trial sites. Appendix B
shows the regimen for (and includes detailed
explanatory notes on) patients converting from
warfarin to rivaroxaban.
Inclusion criteria
1. Patients with thrombotic APS,47 with or without
SLE, who have had either a single episode of
VTE whilst not on anticoagulation or recurrent
episode(s) which occurred whilst oﬀ anticoagula-
tion or on sub-therapeutic anticoagulant therapy
(deﬁnitions are in the Glossary in Appendix C).
2. Patients with a target INR of 2.5 (range 2.0–3.0).
3. Treated with warfarin for a minimum period of
three months since last VTE.
4. Female patients must be using adequate contra-
ception (deﬁned in Appendix C) with the excep-
tion of postmenopausal or sterilized women.
Exclusion criteria (the majority of which are
based on the guidance in the summary of product
characteristics (SPC)19) are listed in Appendix D.
Creatinine clearance is calculated using the
Cockcroft and Gault formula.48,49
Laboratory criteria for aPL diagnosis are detailed
in Appendix E. aPL are reassessed at baseline using
established methods50–54 to deﬁne aPL status at
trial entry.
Duration of treatment and follow-up: Trial treat-
ment will stop at day 180, at which point the
patient will be oﬀered appropriate anticoagulant
care. The trial assessment schedule is summarized
in Table 1 (Appendix F).
Primary outcome measure: Intensity of anticoa-
gulation will be assessed using TG testing, with the
primary outcome the percentage change in ETP
from randomization to day 42. TG testing will be
performed using the calibrated automated throm-
bogram (CAT) system (Thrombinoscope BV,
Maastricht, The Netherlands) as described by
Hemker et al.55 In order to reduce intra-assay vari-
ation, paired samples for each patient will be tested
at the same time. We and others have previously
assessed thrombin generation in warfarinized
patients using a trigger reagent that gives a reaction
concentration of 5 pmol/l tissue factor and 4 mmol/l
phospholipids.56,57
The time point of day 42 (ﬁrst trial visit post-
randomization) was chosen as the therapeutic
eﬀect of rivaroxaban would be expected to be
stable after a minimum of 30 days of rivaroxaban
therapy and would not be inﬂuenced by any resi-
dual warfarin, based on the biological half-lives of
the vitamin K-dependent coagulation factors,
which range from two to ﬁve hours (factor VII)
up to 72 hours (factor II).58
Secondary outcome measures
a. Eﬃcacy: i) recurrent VTE alone; ii) a composite
of recurrent VTE and other thrombotic events
(deﬁned in the Appendix: C); iii) the thrombin
generation curve will also be quantiﬁed in terms
of: the lag-time, the time to peak, and peak
thrombin concentration;55 iv) markers of
in vivo coagulation activation: F1.2, TAT and
D-dimer;31,33–41
b. Safety i) serious adverse events (SAE); ii) all
bleeding events (deﬁned in Appendix C);
c. QoL; EQ-5D-5L;59
d. Laboratory assessment of compliance: i) anti-
Xa assay in patients on rivaroxaban;60 ii)
factor X amidolytic assay as an aPL-indepen-
dent assessment of anticoagulation, in add-
ition to an INR in patients on warfarin;61 iii)
percentage time in therapeutic range (TTR)
between baseline and day 180 in patients on war-
farin using the method described by Rosendaal
et al.62
SAEs: Suspected unexpected serious adverse
reactions (SUSARs) and other serious adverse
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events (SAEs) will be reported to the regulatory
authorities and the research ethics committees, as
appropriate. All SAE reports received from the
study sites will be reviewed by independent medic-
ally qualiﬁed staﬀ. If pregnancies do occur they
should be reported within 24 hours of the investi-
gator becoming aware.
Procedures for assessing QoL: QoL will be eval-
uated via the EQ-5D-5L.59 We believe this might
pick up diﬀerences, particularly in the question on
‘usual activities’ and the visual analogue score.
Sample size: Rivaroxaban would be regarded as
non-inferior to warfarin if the percentage change in
ETP is not more than 20% higher (i.e. less anti-
coagulant eﬀect) than that for warfarin. This non-
inferiority limit of 20% is based on the inter-centre
assay variability of test performance63 and on
clinical relevance. In patients on warfarin, at a com-
parable INR range, six weeks after starting war-
farin treatment the standard deviation of
percentage change in ETP was 36%.42 Using a
one-sided 2.5% signiﬁcance level and 80% power,
51 participants per group are required. Allowing
for 12% non-evaluable patients, a total of 116
patients need to be randomized. The sample size
has not been adjusted for non-compliance since,
unlike in a superiority trial, this would not neces-
sarily reduce the power of a non-inferiority
design.64
Randomization: Randomization will be stratiﬁed
by centre and patient type (SLE/non-SLE) to
ensure balance in treatment arms. Permuted
blocks with a random block length will be used to
allocate patients to treatments within each stratum.
Table 1 RAPS trial assessment schedule
Assessment (Procedure/activity) Screening Baseline
Visit 1 Day 42
(ideally
-12daysþ14 days)
Visit 2 Day 90
(ideally14days)
Visit 3 Day 180
(ideally14days)
Visit 4 Day 210
(ideally14days)
Consent X
Medical History X
Demographics X
Patient review X X X X X X
Height X
Weight X X
BMI X X
Blood pressure X X
FBC X X
U&E, CrCl X X
LFTs X X
Anti-DNA X
aPL X
20mL citrated blood sample for trial
assessments (all patients)
X X
20mL blood sample for the transla-
tional research (optional)
X X
Pregnancy tests X X X
Current medication X X X X X X
Document INRs X X X X
Dispensation rivaroxaban X X
Drug accountability of rivaroxaban X X X
Enquiry for bleeding symptoms X X X X X X
Enquiry for recurrent thrombosis X X X X X X
QoL questionnaire X X
Timing of screening tests:
The following tests are repeated if screening was more than 14 days prior to randomization:
Full blood count (FBC)
Urea and electrolytes (U&E) and creatinine clearance (CrCl) (to be calculated using the Cockcroft & Gault formula)
Liver function tests (LFTs) to include ALT
*Anti-DNA tests no more than three months prior to randomization, i.e. testing for anti-DNA is not required within 30 days prior to
randomisation
**Patients are diagnosed with thrombotic APS (defined in Appendix C) prior to trial entry. Results and dates of routine aPL tests establishing a
diagnosis of thrombotic APS are documented in the CRF (i.e. testing for aPL is not required within 30 days prior to randomisation). aPL are
reassessed at baseline using established methods,50–54 to define aPL status at trial entry (Appendix E).
þINR to be performed only in patients randomised to remain on warfarin
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Statistical analysis
Summary statistics will be calculated for baseline
patient characteristics and study outcomes in each
arm. Numbers and percentages will be used to sum-
marize categorical variables, whilst means/standard
deviations or medians/interquartile ranges will be
used for continuous variables, as appropriate. All
analyses will be performed on an intention-to-treat
basis. No subgroup analyses are planned.
For the primary outcome, a regression model
will estimate the diﬀerence in log-transformed
ETP between the rivaroxaban and warfarin at day
42 with a two-sided 95% conﬁdence interval (CI),
adjusting for stratiﬁcation variables and baseline
ETP. Estimates and 95% CI on the log scale will
be back-transformed to percentage changes for
presentation. Sensitivity analyses for the primary
outcome will consist of: a tobit regression
model,65 which can deal with censored values
below the limit of detection of the assay, a per-
protocol analysis excluding patients who did not
comply with the trial protocol. Interpretation of
the 95% CI for the eﬀect of treatment in a non-
inferiority trial is shown in Figure 2 in Appendix
G.66 Diﬀerences between the two arms for eﬃcacy
and safety secondary outcomes will be presented as
estimates and 95% CIs. Diﬀerences in EQ-5D-5L
QoL scores will be presented as estimates and 95%
CI, adjusting for baseline values and stratifying
variables.
Anti-factor Xa assays in the patients on rivarox-
aban (at day 42) and the INRs and factor X ami-
dolytic assays in patients on warfarin (at baseline
and day 42) will be correlated with log-transformed
ETP to assess relationships with laboratory meas-
ures of compliance.
Changes to the protocol since ﬁrst approval are
detailed in Appendix H.
Discussion
Clinically, our hypothesis is that in patients with
thrombotic APS with previous VTE, rivaroxaban
could induce more predictable anticoagulation,
with additional beneﬁts to patients because there
is no requirement for regular laboratory monitor-
ing of anticoagulation. TG provides a global meas-
ure of anticoagulation, and can therefore assess the
anticoagulant eﬀects of both rivaroxaban and war-
farin (drugs with very diﬀerent modes of action on
the coagulation mechanisms). It has been indicated
that the ETP is an appropriate measure of the
intensity of the anticoagulant eﬀect in individuals
on rivaroxaban.45,46 If we can demonstrate i) that
the anticoagulant eﬀect of rivaroxaban is not infer-
ior to that of warfarin; and ii) the absence of any
adverse eﬀects of rivaroxaban, we believe that this
would provide suﬃcient supporting information to
change practice for APS patients, i.e. to make riv-
aroxaban the standard of care for the treatment of
patients with APS, with or without SLE, who have
VTE requiring a target INR of 2.5, i.e. APS
patients who have had a single VTE episode
whilst not on anticoagulation or recurrent epi-
sode(s) which occurred whilst oﬀ anticoagulation
or on sub-therapeutic anticoagulant therapy.
Secondary laboratory outcome measures of eﬃ-
cacy are also being determined to provide a compre-
hensive assessment of ex vivo thrombin generation
and in vivo coagulation activation. The thrombin
generation curve will therefore also be quantiﬁed
in terms of: the lag-time, the time to peak, and
peak thrombin concentration.55 In addition, mar-
kers of in vivo coagulation activation, F1.2, TAT
and D-dimer will provide supplementary informa-
tion about thrombogenic potential.31,33–41
The question arises as to whether speciﬁc clin-
ical trials are required in patients with thrombotic
APS. Patients with APS are inherently diﬀerent
from other patients with a history of VTE by
virtue of their aPL, particularly LA, which are
known to interfere with a number of haemostatic
mechanisms, and which could therefore potentially
modulate the actions of anticoagulants. VKAs
exert their anticoagulant action by inhibition of
the vitamin K-dependent post-translational
gamma-carboxylation of procoagulant factors II,
VII, IX and X. However, VKAs also reduce the
activity of the major naturally occurring anti-
coagulant protein C/S system (both protein C
and S are vitamin K dependent), which potentially
counterbalances the anticoagulant eﬀects of
VKAs. aPL have been demonstrated to induce
reduced protein C and S activity ex vivo.67–69
Whilst this may not entirely reﬂect the in vivo situ-
ation, it is plausible that aPL may increase the
VKA-induced counterbalancing eﬀect, and thus
potentially shift the equilibrium further away
from anticoagulation. Rivaroxaban and the other
NOACs have very speciﬁc targets (factor Xa for
rivaroxaban, apixaban and edoxaban and the
active site of thrombin for dabigatran)18–21 and
would not be expected to directly inﬂuence protein
C and S activity. As a result, these agents may
have greater anticoagulant eﬃcacy than warfarin
in patients with APS. It is possible that aPL could
directly interfere with the anticoagulant action of
rivaroxaban, although this is unlikely as
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rivaroxaban is a small molecule with high aﬃnity
for its speciﬁc target. The available phase III RCT
of rivaroxaban, or other NOACs, compared
with VKAs in the treatment of VTE may there-
fore not be generalizable to patients with throm-
botic APS where there remains an unmet
need.12–18
The RAPS trial will include patients who have
APS, with or without SLE, currently on warfarin,
target INR 2.5 for previous VTE. Patients will be
randomized to either continue on warfarin or
switch to rivaroxaban. Inclusion of patients with
and without SLE is appropriate for the following
reasons: ﬁrst, many patients with ‘primary’ throm-
botic APS have clinical features such as joint pain
which in eﬀect makes some of these patients ‘lupus
like’. Secondly, our ﬁndings in ‘primary’ throm-
botic APS will be applicable to all APS patients,
i.e. with or without SLE. Of note here, we have
previously established that there is no diﬀerence
in the risk of recurrent thrombosis between patients
with SLE- and non-SLE-associated thrombotic
APS.70 Thirdly, no diﬀerence in the eﬀect of rivar-
oxaban would be expected between patients with
SLE-associated thrombotic APS or thrombotic
APS alone. The randomization will be stratiﬁed
by centre and also by patient type (SLE/non-
SLE), to ensure a balance of patients in each arm
for each centre and patient type.
At the end of the trial treatment period of six
months, patients will be oﬀered appropriate anti-
coagulant care determined on an individualized
basis based on a number of factors, including feed-
back from the patients on their experience with
rivaroxaban during the trial.
Monitoring, trial approvals and registrations are
summarized in Appendix I.
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